ArticleHeart rhythm O22021
Catheter ablation and healthcare utilization and cost among patients with paroxysmal versus persistent atrial fibrillation.
Article in Heart rhythm O2, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Considering User Experience and Behavioral Approaches in the Design of mHealth Interventions for Atrial Fibrillation: Systematic Review.Journal of medical Internet research · 2024Pooled it
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Guideline
- Impact of atrioventricular node ablation and permanent pacing on clinical outcomes, quality of life, and health care utilization in patients with atrial fibrillation.Heart rhythm O2 · 2026Article
- Early Rhythm Versus Rate Control in Older Adults With New-Onset Atrial Fibrillation: A Propensity Score-Matched Analysis.Journal of arrhythmia · 2026Article
- Acute atrial fibrillation and flutter treated electively: rationale and design of the randomized controlled AFFELECT trial.European heart journal open · 2026Article
- Recent-onset atrial fibrillation: challenges and opportunities.European heart journal · 2026Review
- New recommendations for rhythm control-What has changed in the 2023 ACC/AHA/ACCP/HRS and 2024 ESC guidelines for atrial fibrillation, and where does dronedarone fit in?American heart journal plus : cardiology research and practice · 2025Article
- A Cost Analysis of Catheter Ablation for Atrial Fibrillation: A Canadian Pre-Post Study.CJC open · 2024Article
- Ablation to Reduce Atrial Fibrillation Burden and Improve Outcomes: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2023Review
- Variation and clinical consequences of wait-times for atrial fibrillation ablation: population level study in Ontario, Canada.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Observational
- Addition by Subtraction: Disease Progression and the Value of Atrial Fibrillation Ablation.Circulation. Arrhythmia and electrophysiology · 2023Article
- Economic and Health Value of Delaying Atrial Fibrillation Progression Using Radiofrequency Catheter Ablation.Circulation. Arrhythmia and electrophysiology · 2023Article
- Race and Ethnic and Sex Differences in Rhythm Control Treatment of Incident Atrial Fibrillation.ClinicoEconomics and outcomes research : CEOR · 2023Article
- Healthcare Utilization and Outcomes in Atrial Fibrillation Patients Treated by Drug Therapy versus a Catheter Ablation Strategy-A Middle European Propensity Score Matched Cohort Study.Journal of cardiovascular development and disease · 2022Article
- Economic Evaluation of Contact Force Catheter Ablation for Persistent Atrial Fibrillation in the United States.Heart rhythm O2 · 2022Article
- Impact of a dedicated atrial fibrillation clinic on diagnosis-to-ablation time.Heart rhythm O2 · 2022Article
- Catheter ablation using advanced porous tip contact force-sensing radiofrequency catheter: Impact on health care utilization among patients with persistent atrial fibrillation.Heart rhythm O2 · 2022Article
- Racial Disparity in Referral for Catheter Ablation for Atrial Fibrillation at a Single Integrated Health System.Journal of the American Heart Association · 2022Article
- Impact of Catheter Ablation on Quality of Life and Healthcare Utilisation.Arrhythmia & electrophysiology review · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAblation reduces atrial fibrillation (AF) burden and improves health-related quality of life. The relationship between ablation, healthcare utilization, and AF type (paroxysmal AF [PAF] vs persistent AF [PsAF]) remains unclear.
objectiveTo compare changes in AF-related healthcare utilization and costs from preablation to postablation among patients with PAF and PsAF.
methodsPatients (2794 PAF, 1909 PsAF) undergoing ablation (2016-2018) were identified using the Optum database. Outcomes included inpatient admissions, emergency department (ED) visits, office visits, cardioversion, and antiarrhythmic drug (AAD) use. Costs (2018 US$) and outcomes were compared for the year before/after ablation using the McNemar test and Wilcoxon signed rank test.
resultsCompared to PAF patients, PsAF patients were older (68.6 ± 9.0 years vs 67.4 ± 9.9 years,
conclusionSignificant reductions in healthcare utilization and costs were observed among PAF and PsAF patients undergoing ablation. These data suggest a strategy of earlier ablation may reduce long-term healthcare utilization and costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.